- Home
- STG vs MEIP Comparison
STG vs MEIP Comparison
Compare STG & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- MEIP
- Stock Information
- Founded
- STG 2003
- MEIP 2000
- Country
- STG China
- MEIP United States
- Employees
- STG N/A
- MEIP N/A
- Industry
- STG Other Consumer Services
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- MEIP Health Care
- Exchange
- STG Nasdaq
- MEIP Nasdaq
- Market Cap
- STG 130.7M
- MEIP 153.9M
- IPO Year
- STG 2018
- MEIP 2003
- Fundamental
- Price
- STG $10.11
- MEIP $4.97
- Analyst Decision
- STG
- MEIP
- Analyst Count
- STG 0
- MEIP 0
- Target Price
- STG N/A
- MEIP N/A
- AVG Volume (30 Days)
- STG 14.7K
- MEIP 574.2K
- Earning Date
- STG 08-14-2025
- MEIP 09-18-2025
- Dividend Yield
- STG N/A
- MEIP N/A
- EPS Growth
- STG N/A
- MEIP N/A
- EPS
- STG 3.59
- MEIP N/A
- Revenue
- STG $279,374,215.00
- MEIP N/A
- Revenue This Year
- STG N/A
- MEIP N/A
- Revenue Next Year
- STG N/A
- MEIP N/A
- P/E Ratio
- STG $2.81
- MEIP N/A
- Revenue Growth
- STG N/A
- MEIP 33.76
- 52 Week Low
- STG $4.25
- MEIP $1.46
- 52 Week High
- STG $15.00
- MEIP $9.00
- Technical
- Relative Strength Index (RSI)
- STG 54.01
- MEIP 54.29
- Support Level
- STG $8.89
- MEIP $4.45
- Resistance Level
- STG $10.70
- MEIP $5.19
- Average True Range (ATR)
- STG 0.76
- MEIP 0.35
- MACD
- STG -0.04
- MEIP -0.12
- Stochastic Oscillator
- STG 58.52
- MEIP 47.27
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.